Table 2.

FRDA patient details

Subject	Age at assessment (years), gender	Age at onset (years)	Disease duration (years)	GAA1	GAA2	SARA
FRDA1*	18, F	11	7	100	650	12
FRDA2*	36, F	2	34	150	850	26
FRDA3*	17, M	4	13	220	220	27.5
FRDA4*	48, F	17	31	400	834	30
FRDA5*	42, F	17	25	400	800	23
FRDA6*	45, F	15	30	467	967	26
FRDA7**	37, F	19	28	567	900	30
FRDA8**	40, M	20	20	567	967	20
FRDA9**	21, M	6	15	580	745	23
FRDA10**	30, M	11	19	634	767	30
FRDA11**	58, F	15	43	683	983	40
FRDA12**	18, M	5	15	700	850	16
FRDA13***	40, F	8	32	720	920	39
FRDA14***	28, F	5	23	745	945	29
FRDA15***	34, M	8	26	785	785	30
FRDA16***	26, M	8	18	800	867	26.6
FRDA17***	51, F	7	44	820	820	37
FRDA18***	24, F	12	12	834	1034	17
FRDA19***	41, M	7	34	834	1167	38
FRDA20***	20, M	8	12	850	850	20.5
FRDA21***	22, M	15	7	850	1200	21.5
FRDA22***	30, M	11	19	850	1350	36
FRDA23***	50, M	13	37	850	1050	28
FRDA24***	31, F	22	9	1000	1000	21
FRDA25***	25, F	7	18	1000	1200	40
FRDA26***	31, F	3	28	1020	1220	40
FRDA27***	21, M	5	16	1050	1680	29

*, GAA1 < 500; **, GAA1 500–700; ***GAA1 > 700